Particularly, patients with NAFLD, including fatty liver and steatohepatitis, have significantly higher serum FGF21 values than control subjects, which could prove useful for the non-invasive prediction of steatosis and fibrosis status in NAFLD (18). Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.